Southern University of Science and Technology Hospital (SUSTech Hospital): Precision Targeted Oncology & Immuno-Oncology Center in Shenzhen

Southern University of Science and Technology Hospital (SUSTech Hospital / 南方科技大学医院) is a premier Grade 3A tertiary comprehensive university hospital directly affiliated with the Southern University of Science and Technology (SUSTech), one of China's most innovative research universities. Located in the innovation and university corridor of Nanshan District, Shenzhen, SUSTech Hospital integrates clinical medicine, scientific translational research, and higher medical education, rapidly emerging as a high-technology medical powerhouse in the Guangdong-Hong Kong-Macao Greater Bay Area.

1. High-Level Oncology Center & Specialist Leadership

The Oncology Medical Center (肿瘤医学中心) at SUSTech Hospital is positioned as an elite academic oncology service. Backed by the university's substantial scientific resources and talent-attraction programs, the department has built a core team of senior oncology professors, doctoral supervisors, and chief physicians from China's foremost oncology hospitals:

• Senior Expert Clinical Teams: Providing deep clinical diagnostic acumen and personalized chemotherapy, targeted therapy, and immunotherapy design for patients with early, locally advanced, or widely metastatic malignancies.
• Translational Medicine Integration: Bridging molecular oncology research with clinical therapeutics to explore drug-resistance mechanisms, tumor heterogeneity, and novel therapeutic targets.
• Standardized & Compassionate Inpatient Care: Dedicated oncology inpatient units equipped with modern patient monitoring, advanced infusion systems, pain management protocols, and psychological support services.

2. Core Strengths: Precision Targeted Therapy & Genomic Profiling

Targeted therapy forms the cornerstone of SUSTech Hospital's precision oncology protocols, providing patients with customized molecular treatment maps rather than one-size-fits-all treatments:

• Next-Generation Sequencing (NGS) & Biomarker Mapping: Routine testing for actionable driver mutations across EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, BRCA, and NTRK gene alterations across solid tumors.
• Liquid Biopsy & ctDNA Dynamic Monitoring: Non-invasive monitoring of circulating tumor DNA (ctDNA) during targeted treatment courses to detect early signs of resistance before radiologic progression appears on CT or MRI.
• Overcoming Targeted Drug Resistance: Formulating individualized subsequent-line targeted strategies (such as next-generation third- or fourth-generation tyrosine kinase inhibitors, antibody-drug conjugates [ADCs], or multi-target combination regimens).
• Broad Solid Tumor Coverage: High specialization in non-small cell lung cancer (NSCLC), colorectal adenocarcinoma, gastric cancer, breast cancer, hepatocellular carcinoma (HCC), and renal cell carcinoma.

3. Advanced Immuno-Oncology & Combination Protocols

Immuno-oncology at SUSTech Hospital emphasizes maximizing antitumor immune responses while maintaining stringent safety control over immune-related adverse events (irAEs):

• Multi-Target Immunotherapy Regimens: Experienced deployment of PD-1 / PD-L1 inhibitors, CTLA-4 inhibitors, novel checkpoint blockers, and domestic Chinese innovative bi-specific antibodies.
• Synergistic Combination Therapies: Combining immune checkpoint inhibitors with anti-angiogenic targeted agents (VEGF/VEGFR inhibitors), regional hepatic arterial infusions, low-dose metronomic chemotherapy, or localized radiotherapy to turn "cold" immunologically inert tumors into responsive "hot" tumors.
• Systemic irAE Multidisciplinary Vigilance: Structured rapid-response protocols involving pulmonologists, endocrinologists, gastroenterologists, and rheumatologists to promptly diagnose and safely manage checkpoint inhibitor-related pneumonitis, colitis, hepatitis, or thyroid dysfunction.

4. Comprehensive Multidisciplinary Tumor Board (MDT)

SUSTech Hospital enforces a multidisciplinary tumor board (MDT) model for all challenging, recurrent, and metastatic cancer cases. The board convenes:

• Medical Oncology: Systemic precision targeted therapy, immunotherapy, and maintenance protocols.
• Surgical Oncology & Minimally Invasive Surgery: Laparoscopic and thoracoscopic organ-sparing tumor resections, lymphadenectomy, and restorative reconstructions.
• Interventional Oncology & Radiology: Transcatheter arterial chemoembolization (TACE), percutaneous microwave / radiofrequency thermal ablation, and radioactive seed implantation for localized liver, lung, and retroperitoneal lesions.
• Pathology & Molecular Diagnostics: Rapid immunohistochemistry (IHC) profiling, fluorescence in situ hybridization (FISH), and comprehensive genomic pathology reports.

5. Location, Access & Hospital Overview

Situated in the heart of Shenzhen's high-technology corridor, SUSTech Hospital provides convenient domestic and regional access:

• Address: No. 6019 Liuxian Avenue, Nanshan District, Shenzhen, Guangdong Province, China (深圳市南山区留仙大道6019号).
• Transportation Links: Direct access via Shenzhen Metro Line 5 (University Town / Tanglang stations nearby), approximately 15 minutes by car to Shenzhen North High-Speed Railway Station, and 30 minutes to Shenzhen Bao'an International Airport (SZX). Convenient transit connections are also available to the Hong Kong Lok Ma Chau and Shenzhen Bay border crossings.
• Campus Environment: A modern architectural campus featuring landscaped patient healing gardens, quiet private suites, modern diagnostic centers, and streamlined outpatient registration channels.

6. Preparing Medical Records for Oncology Coordination

To ensure a swift, accurate assessment by SUSTech Hospital's oncology specialists and MDT panel, international and nonlocal patients are advised to prepare:

• Histopathology & Immunohistochemistry (IHC) Reports: Core needle biopsy or surgical pathology reports, including microscopic descriptions and diagnostic biomarker stains.
• Molecular & NGS Genetic Testing Reports: Any prior genomic testing results detailing actionable mutations, TMB (tumor mutational burden), and MSI/dMMR status.
• Diagnostic Imaging: High-resolution CT, MRI, or PET-CT scan series (DICOM files preferred on USB/cloud drive) within the past 1 to 3 months, accompanied by formal radiologist reports.
• Treatment Chronology: A sequential list of prior chemotherapy regimens, targeted drug brands and dosages, immunotherapy cycles, radiation therapy summaries, and dates of surgical interventions.

Disclaimer: China Medical Concierge – Shanghai (CMCS) is an independent medical concierge and healthcare management consulting service. CMCS is not an affiliated healthcare provider or hospital branch. All diagnostic procedures, targeted therapy prescriptions, and immuno-oncology treatment plans are determined and administered exclusively by licensed medical professionals at Southern University of Science and Technology Hospital.